19 studies were found.

1.		No longer recruiting	Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma Condition: Multiple Myeloma
2.		No longer recruiting	Anti-Angiogenesis Therapy Using Thalidomide in Patients with Waldenstrom’s Macroglobulinemia Condition: Waldenstrom Macroglobulinemia
3.		Recruiting	Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide Condition: Multiple Myeloma
4.		Recruiting	Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide Condition: Multiple Myeloma
5.		No longer recruiting	D.T. PACE versus High Dose Melphalan and Autologous Transplant in Patients with Previously Treated Multiple Myeloma Condition: Multiple Myeloma
6.		No longer recruiting	DCEP in Combination with Thalidomide as Salvage Therapy for Post Transplantation Relapse Condition: Multiple Myeloma
7.		No longer recruiting	Dexamethasone or Dexamethasone in Combination with Thalidomide as Salvage Therapy Condition: Multiple Myeloma
8.		No longer recruiting	DTPACE followed by Tandem Transplant with MEL 200 versus MEL/DTPACE Hybrid and DTPACE Consolidation Condition: Multiple Myeloma
9.		Completed	Effect of Activity on Sleep of Cognitively-Impaired Veterans Conditions: Alzheimer's Disease; Sleep Disorders
10.		No longer recruiting	An Open Protocol for the Compassionate Use of Thalidomide for Patients with Advanced or Refractory Malignancies Condition: Multiple Myeloma
11.		Recruiting	Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II Condition: Multiple Myeloma
12.		Recruiting	Study of Combination PS-341 and Thalidomide in Multiple Myeloma Condition: Multiple Myeloma
13.		Recruiting	Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant Condition: Multiple Myeloma
14.		Not yet recruiting	Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination with DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma Condition: Multiple Myeloma
15.		Recruiting	Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally Condition: Multiple Myeloma
16.		Completed	Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease Condition: refractory plasma cell neoplasm
17.		No longer recruiting	Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia Condition: Leukemia
18.		No longer recruiting	Total Therapy II Condition: Multiple Myeloma
19.		Recruiting	UARK 2003-33, Total Therapy III Condition: Multiple Myeloma